Health

Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide

Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed * Adoption of Remplir™ among Australian urologists is accelerating, with ~100 surgeries conducted by surgeons nationwide. * This promising new applicatio...

2025-11-20 13:52 665

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

DURHAM, N.C. and SEOUL, South Korea, Nov. 20, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation i...

2025-11-20 13:01 1374

Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs

SHANGHAI and HONG KONG, Nov. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...

2025-11-20 10:56 855

WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry

WuXi AppTec sets new benchmarks in strategic execution and technological advancement, further strengthening its ability to support innovators worldwide as they deliver breakthrough medicines for patients. SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan

2025-11-20 10:00 715

USANA Named No. 1 Dietary Supplements Brand in the Philippines for the 7th Consecutive Year

Euromonitor Recognizes USANA Philippines as the Market Leader from 2019 to 2025 MANILA, Philippines, Nov. 20, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in health and wellness, has once again been recognized as the No. 1 dietary supplements brand inthe Philippines* by Eurom...

2025-11-20 09:16 707

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] wo...

2025-11-20 03:00 1088

Dimora Medical Supports HS Connect Empower Workshop to Promote Science-Based Care for Hidradenitis Suppurativa Patients

NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Patient-centered nonprofit organization HS Connect recently hosted the Empower HS: Knowledge and Advocacy Workshop, an educational event designed to help individuals living with Hidradenitis Suppurativa (HS) and their caregivers gain the knowledge and confi...

2025-11-20 01:48 985

NABR: CITES Standing Committee Issues Assessment of Long-Tailed Macaque Monkey Breeding Practices

WASHINGTON, Nov. 20, 2025 /PRNewswire/ -- The Standing Committee of CITES, an international body responsible for monitoring trade in animal species, announced the results of its review of animal breeding practices inCambodia, thankingCambodia for providing extensive data and relying on science. T...

2025-11-20 01:33 861

BestQool Announces Up to 21% Off Red Light Therapy Devices on Amazon for Black Friday

NEW YORK, Nov. 19, 2025 /PRNewswire/ -- This Black Friday, BestQool invites everyone to pause, breathe, and take a moment for themselves. Even a brief daily red light therapy session ca...

2025-11-19 23:04 643

HKUST Commences Preparations for New Medical School

Inaugural Cohort in 2028, Cultivating Clinically Excellent and Technology-Savvy Doctors of the Future HONG KONG, Nov. 19, 2025 /PRNewswire/ -- With the support of the HKSAR Government, TheHong Kong University of Science and Technology (HKUST) has commenced preparations to establish a new medical...

2025-11-19 22:55 611

Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein and anti...

2025-11-19 22:17 852

Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery

Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...

2025-11-19 20:08 588

The Rise of Advanced Maternal Age IVF: BaseCare Medical'-B(2170.HK) AI "Undisturbed Culture" Empowers Intelligent Assisted Reproduction

SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Data from the keynote report at the 18th Annual Conference of the Chinese Society of Reproductive Medicine (CSRM2025), held fromNovember 12th to 15th, indicates that the average treatment age for women undergoing IVF inChina has risen to 33.6 years, h...

2025-11-19 19:50 692

Waterdrop Inc. to Report Third Quarter 2025 Financial Results on December 3, 2025

BEIJING, Nov. 19, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform d...

2025-11-19 18:00 1811

KHB Highlights the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer at MEDICA 2025

XI'AN, China, Nov. 19, 2025 /PRNewswire/ -- Shanghai Kehua Bio-engineering Co., Ltd. (KHB), a global provider of in-vitro diagnostic (IVD) solutions, is showcasing its latest compact chemiluminescence platform—the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer—at MEDICA 2025, one o...

2025-11-19 17:02 769

BIOVOZ and the University of Auckland Join Forces to Lead the Next Frontier in Anti-Aging Research

From Ingredient Supplementation to Gene Regulation: BIOVOZ and the University of Auckland Pioneer a New Era in Beauty Science AUCKLAND, New Zealand, Nov. 19, 2025 /PRNewswire/ -- Leading beauty brand BIOVOZ has announced a strategic research partnership with the University ofAuckland, marking a ...

2025-11-19 15:02 576

Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care

JERUSALEM, Nov. 19, 2025 /PRNewswire/ -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by theBiomedical Advanced Research and Developmen...

2025-11-19 13:01 412

Older Singaporeans Support Healthier SG, but Lifestyle Habits Still Lag Behind

* New SMU research reveals critical gaps in preventive health, lifestyle habits, and continuity of care asSingapore transitions into a super-aged society. * Despite strong pro-health policies, everyday adoption - especially among older adults - remains limited. * Bridging this gap requires ...

2025-11-19 12:30 670

Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restric...

2025-11-19 08:00 895

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

SYDNEY, Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxali...

2025-11-19 05:15 1923
1 ... 567891011 ... 873